Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome.

Collegium antropologicum - 1 Sept 2007

Radaković Branko, Goldstajn Marina Sprem

Abstract excerpt

Combined oral contraceptives (Ocs) are the most commonly used androgen suppressors and the treatment of choice for menstrual dysfunction in women with polycystic ovarian syndrome (PCOs). Although OCs have remained popular due to their convenience and effectiveness, there have been continuing concerns about adverse effects. The OCs have long been known to incur and increased risk of venous thromboembolism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Contraindications
Share to Genetic Predisposition to Disease
Share to Hyperhomocysteinemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Plasminogen Activator Inhibitor 1

Share to Polycystic Ovary Syndrome

Share to Thromboembolism

Share to Thrombophilia

Source

Identifiers

PMID: 18041407

Genes

MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome.PMID 18041407Read ↗

Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome.Semantic proximity Read ↗

Polycystic ovarian syndrome and thrombophilia.Semantic proximity Read ↗

Association of single nucleotide polymorphisms (4G/5G) of plasminogen activator inhibitor-1 and the risk factors for placenta-related obstetric complications.Semantic proximity Read ↗

Thrombophilia-related gene variants may be linked to polycystic ovary syndrome susceptibility and its related traitsSemantic proximity Read ↗

Thrombophilia-related gene variants may be linked to polycystic ovary syndrome susceptibility and its related traitsSemantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.Semantic proximity Read ↗

Thrombophilia-related gene variants may be linked to polycystic ovary syndrome susceptibility and its related traits.Semantic proximity Read ↗

Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in iranian women with polycystic ovary syndrome.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.Semantic proximity Read ↗

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.Semantic proximity Read ↗

4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.Semantic proximity Read ↗

The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.